Focus  by Shouval, Daniel
FocusFocus
Daniel Shouval⇑
Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, IsraelChronic hepatitis C in the elderly patient: To treat or not to
treat?
More than 10 years have passed since the completion of the reg-
istration trials for the treatment of chronic hepatitis C (CHC) with
pegylated interferon and ribavirin. During this period, a wealth of
information has been further collected in community based trials
regarding the predictors for response to anti-viral therapy. Fac-
tors associated with a favorable response to therapy, identiﬁed
mainly through multivariate analysis in different trials, include
infection with HCV genotypes 2 and 3, viral load <600,000 IU/
ml, age <40 years, female gender, non-African American origin,
body weight <75 kg, absence of insulin resistance, absence of
bridging ﬁbrosis upon liver biopsy, elevated ALT >3X of ULN, riba-
virin dose >10.6 mg/day, pegylated interferon dose (of one brand)
of 1.5 lg/kg/week, and compliance [1]. The introduction into clin-
ical practice of some new means for identiﬁcation of potential
responders (i.e. analysis of IL28B polymorphism [2]) and the
pending registration of new anti-viral protease inhibitors will
have a major impact on predictors of response to therapy and
are expected to revolutionize the response rates to treatment of
CHC. However, most probably it will take a number of years until
the fruits of these achievements will reach the common CHC
patient. Meanwhile it is well known that prevalence of HCV
increases with older age and older age has been reported in a
number of studies as a relatively unfavorable predictor for
response to conventional anti-viral therapy which is also associ-
ated with decreased tolerance to treatment [3–9]. Thus, at pres-
ent, a large number of older patients, 60 years of age or older,
are at risk for developing cirrhosis and hepatocellular carcinoma,
and cannot wait for the introduction of the new anti-viral agents
into clinical practice. The optimal selection of candidates for anti-
viral therapy in aged CHC patients remains an ongoing challenge
for clinicians. Caretakers of such patients must take into account
a large number of factors which affect success of therapy [1] in
addition to the special situation in the case of a diseased and
aging liver [9,10].
In the present issue of the Journal, Oze and co-workers report
their retrospective experience in 240 Japanese patients >65 years
old, treated with pegylated interferon and ribavirin. Results were
compared to data obtained in 800 patients younger than 65 years
old. Patients were classiﬁed into ﬁve groups according to age.Journal of Hepatology 20
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mainly due to anemia. SVR rates in genotype 1 patients declined
from 42–46% in patients <65 years old to 26–29% in those >65
years old. SVR rates correlated with at least a 1-log decrease of
viral load at week 4 or a 2 log decrease at week 8. In a smaller
group of genotype 2 patients <70 years of age, SVR rates fell from
70% in patients <70 years to 43% in patients >70 years old. The
authors conclude that despite the reduced SVR rates in older CHC
patients, week 4/week 8 response guided therapy is a practical
approach for the prediction of successful treatment in genotype
1 and 2 patients above the ages of 65 and 70 years, respectively.
The investigators suggest incorporating this response guided
strategy into the clinical practice of older patients. A similar rec-
ommendation was recently suggested in a letter to the editor by
Antonucci and co-workers [4]. They analyzed the impact of age in
62 Italian genotype 1 and 4 patients (ages 25–75 years) as a pre-
dictor of SVR with respect to a drop in viral load on day 28 [4]. In
this relatively small study, the 28 day decrease in HCV viral load
following anti-viral treatment was signiﬁcantly worse in patients
over 40 years old. The investigators believe that this age depen-
dent difference in response rates cannot be explained on the basis
of age differences alone. They suggest that age speciﬁc differences
in the interaction between virus and host immune response may
contribute to the differences in response rates to treatment
between younger and older patients.
Hoofnagle and co-workers have recently studied the early
changes in HCV viral load during the ﬁrst 28 days after initiation
of anti-viral treatment in 341 genotype 1 patients who received
treatment without dose modiﬁcation [11]. In this study, African
Americans with a similar 28-day decrease in viral load as white
patients were less likely to achieve an SVR. The investigator sug-
gests that this reduced responsiveness to anti-viral therapy may
be due to unresponsiveness to intracellular actions of interferon
in African Americans.
Taking together the results obtained in the above three studies
(whichhavenot evaluated the IL28B status in these populations), it
is tempting to speculate that the reduced responsiveness to anti-
viral treatment in older CHC patients and in African Americans is
driven by similar mechanism(s), at least during the ﬁrst 28 days
of therapy. However, before taking this hypothesis too far, we
should take into account that other factors associatedwith a smal-
ler decrease of HCV-RNA during the ﬁrst 4 weeks of therapy have
already been well established including high baseline viral load,
advanced hepatic ﬁbrosis, and overweight.
Regardless of the mechanism(s) involved in the reduced
responsiveness to anti-viral therapy in the aging CHC patient,11 vol. 54 j 597–598
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the reports of Oze and Antonucci provide a clear message for the
clinician: older patients with chronic hepatitis C are candidates
for response tailored anti-viral therapy which preferably should
be evaluated after the ﬁrst 4 weeks of treatment taking into
account a sound clinical judgment and other predictors for the
response mentioned above.Transient elastography for non-invasive diagnosis of ﬁbrosis
and cirrhosis: Expectations versus performance
Identiﬁcation of the presence and degree of liver ﬁbrosis is a nec-
essary step in the diagnosis and more importantly in the planning
of treatment and follow-up of patients with chronic liver disease.
Until recently, a liver biopsy was, and in the view of many, still is
considered the gold standard for diagnosis of ﬁbrosis. In view of
the known limitations including a small, albeit non-negligible risk
of performing a liver biopsy, there is currently an ongoing effort for
developing new non-invasive tools for the assessment of liver
ﬁbrosis [12]. Among these newmethods currently in development
or already introduced into clinical practice in several countries,
transient elastography (TE), ﬁrst described in 2003 [13], is captur-
ing the attention of clinicians worldwide. This attention is
reﬂected in hundreds of publications on the subject and so far in
59 PubMed reviews including three meta-analyses on TE.
In the present issue of the Journal, Tsochatzis and co-workers
present the fourth meta-analysis published in a relatively short
period of time of less than 4 years which evaluates the accuracy
of TE in the diagnosis of cirrhosis as well as the severity of ﬁbrosis
in patients with chronic liver disease of various etiologies. In the
report discussed herewith, the authors have screened 1289 study
reports including 398 duplicates and selected 40 investigations
with a maximal 3 months interval and deﬁned comparison
between a liver biopsy and TE. This most recent meta-analysis
differs from previous attempts in a number of parameters includ-
ing, among others, the methodology and the inclusion of 29 dif-
ferent studies with an overlap of about 25%. Space does not
permit going into detail of this well described effort, which
includes a wealth of information for the interested reader. The
main results of this study revealed a sensitivity and speciﬁcity
of 0.79 and 0.78 for the F2 stage, and 0.83 and 0.89 for cirrhosis,
respectively. Cut-off values for individual ﬁbrosis stages could
not be validated due to a relatively wide overlap within and
between stages. A similar observation was reported by Fried-
rich-Rust and co-workers who in their meta-analysis described
a high variation of the AUROC in patients at various stages of
ﬁbrosis [14].
The main message in this article for the practicing hepatolo-
gist is that transient elastography has a good sensitivity and spec-
iﬁcity for establishing the diagnosis of cirrhosis. However, in view598 Journal of Hepatology 201of the fact that so far there is a lack of validation for liver stiffness
in the various stages, TE cannot at present be recommended as a
reliable tool for the diagnosis and, no less important, for the fol-
low-up of ﬁbrosis in the individual patient.Conﬂict of interest
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